China’s Institute of Materia Medica Partners With Cyclica on Innovative Drug Repurposing for COVID-19
This post was adapted from its original source on Business Wire and can be viewed here. TORONTO & BEIJING – (March 5, 2020) – The epidemic of COVID-19 remains a prominent healthcare challenge, affecting more than 70 countries and regions over the world. This rapid widespread has made more countries realize the need for international […]
Cyclica and AUM Biosciences to Partner on Developing Novel Cancer Therapies with Greater Precision and Speed, under Project Nexus
This post was adapted from its original source on Business Wire and can be viewed here. TORONTO & SINGAPORE – (January 15, 2020) – AUM Biosciences (AUM), a Singapore-headquartered clinical-stage biotechnology company committed to speedily developing affordable cancer therapies, and Cyclica, a Toronto-based biotechnology company leveraging AI and computational biophysics to decentralize drug discovery, today announced […]
Translational Medicine Accelerator and Cyclica Partner to Form Rare Diseases Medicine Accelerator to Advance the Discovery of Novel Therapies for Rare Diseases
This post was adapted from its original source on Business Wire and can be viewed here. TORONTO & BOSTON – (January 8, 2020) – The Translational Medicine Accelerator (TMA) and Cyclica are proud to announce the formation of the Rare Diseases Medicine Accelerator (RDMA), a joint venture that will be focused on accelerating the discovery of […]
In an Industry Shake Up, Cyclica Announces the Addition of Dr. Melissa Landon, former Director of Applications Science at Schrödinger, as VP, Chief Strategist
This post was adapted from its original source on Business Wire and can be viewed here. TORONTO, CANADA – (January 6, 2020) – Cyclica is pleased to announce Dr. Melissa Landon as VP, Chief Strategist. Melissa brings to Cyclica a wealth of strong scientific expertise in informatics, computational chemistry, and structural biology, along with extensive […]
ATAI Life Sciences and Cyclica Launch Joint Venture to Revolutionize Drug Development for Mental Health Disorders
This post was adapted from its original source on Business Wire and can be viewed here. BERLIN & TORONTO – (November 11, 2019) – ATAI Life Sciences AG, a global biotech platform that envisions an end to mental illnesses, and Cyclica Inc., a leading biotechnology company that leverages artificial intelligence and computational biophysics to streamline the […]
South Korean Company, Yuhan Pharmaceuticals Partners with Cyclica to Advance R&D Across Two Separate Programs for Oncology
This post was adapted from its original source on Business Wire and can be viewed here. TORONTO, CANADA & SEOUL, SOUTH KOREA – (November 7, 2019) – Renowned South Korean healthcare company, Yuhan Pharmaceuticals (Yuhan) and Cyclica Inc. (Cyclica), a leading neo biotechnology company announce a collaboration to apply Cyclica’s proprietary AI-integrated drug discovery platform in […]
Cyclica Collaborates With Enamine to Use REAL Technology in Its Ligand Design Platform for AI-augmented Drug Design
This post was adapted from its original source on Business Wire and can be viewed here. TORONTO, CANADA & KYIV, UKRAINE – (November 5, 2019) – Cyclica, Inc. today announced a collaboration with Enamine Ltd., the world’s largest chemical supplier, to explore its huge readily accessible chemical space using Cyclica’s state-of-the-art AI-driven Ligand DesignTM platform. The […]
To Build Stronger Partnerships Globally, Cyclica Appoints Long Time Pharma R&D Leader Vern De Biasi as VP, Global Head of Strategic Partnerships
This post was adapted from its original source on Business Wire and can be viewed here. TORONTO, CANADA – (October 8, 2019) – Vern brings to Cyclica a rich diversity of expertise in executing digital initiatives and strategic innovation with over 20+ years of experience working with internationally recognized pharmaceutical companies. Prior to this role, Vern […]
Cyclica Announces the Second Year of Ligand Express Academic Polypharmacology (LEAP) Program under Cyclica Academic Partnership Program (CAPP)
TORONTO, ON, CANADA (August 14, 2019) – Cyclica Inc. is pleased to announce the second year of Ligand Express Academic Polypharmacology (LEAP) Program under the Cyclica Academic Partnership Program (CAPP). For its second consecutive year, the LEAP program will invite selected academic partners to access Cyclica’s flagship proteome screening platform, Ligand Express®, which has been […]
Cyclica Announces DANCE (Design Advanced Novel Chemical Entities) Program under Cyclica Academic Partnership Program (CAPP)
TORONTO, ON, CANADA (August 1, 2019) – Cyclica is pleased to announce the Design Advanced Novel Chemical Entities (DANCE) program under the Cyclica Academic Partnership Program (CAPP). Cyclica’s new CAPP now includes both DANCE and LEAP programs, which together provide selected academic partners with an end-to-end enabling drug discovery platform to design advanced lead like […]